Table 1.

LLC cell DHA metabolite concentration (ng/10⁵ cell) determined by LC-MS/MS

Oxylipin	LLC-GFP	LLC-GFP treat with DHA	LLC-mfat-1
10-HDoHE	0.34 ± 0.20	1072.73 ± 245.41**	736.22 ± 205.21**
10S,17S-DiHDoHE	NP	8.75 ± 3.54**	NP
11-HDoHE	NP	1300.73 ± 254.98**	NP
13-HDoHE	0.56 ± 0.39	734.25 ± 261.61**	575.98 ± 272.13**
14-HDoHE	0.46 ± 0.32	454.98 ± 197.20*	179.32 ± 92.18**
17-HDoHE	1.31 ± 0.74	1674.18 ± 492.10**	661.26 ± 133.4**
20-HDoHE	1.00 ± 0.63	2567.3 ± 438.31**	822.19 ± 212.35**
4-HDoHE	2.93 ± 1.10	5175.27 ± 475.64**	1634.9 ± 773.01**
7-HDoHE	0.59 ± 0.34	2020.17 ± 293.62**	536.16 ± 124.03**
8-HDoHE	2.57 ± 1.65	5847.24 ± 425.41**	1298.76 ± 235.18**
Maresin	NP	NP	NP
RvD1	NP	2.18 ± 0.59**	1.07 ± 0.32**
RvD2	NP	NP	NP
16,17-EDP	0.76 ± 0.55	1079.19 ± 333.12**	343.23 ± 83.43**
19,20-EDP	1.43 ± 0.42	3858.48 ± 419.96**	1131.8 ± 241.57**

^*P < 0.05, ^**P < 0.01 compared with LLC-GFP. Data are mean ± SD. NP No peak, CYP Cytochrome P450 enzymes, COX Cyclooxygenase, LOX Lipoxygenase, PG Prostaglandin